Chalcone (1,3-diphenylprop-2-en-1-one) compounds are of natural or synthetic origins and possess a diversity in bioactivities. Recently, the inhibitory activities of heterocyclic chalcones against different cancer cell lines have raised much concern.
INTRODUCTION
The devastating ravages of cancer have become a current major problem the global human population is facing. Statistics show that cancer is second only after cardiovascular disease as the leading cause of death in the U.S. and the leading cause of death in the UK. 1, 2 Some of the dominant drawbacks of present anticancer drug therapy involve their lack of significant greater toxicity towards cancer cells in comparison with normal tissue and the rise of multi-drug resistance. Tumor-selective cytotoxic agents whose structures are sufficiently different from anticancer medication currently on the market are therefore highly sought. Chalcones, also known as α,β-unsaturated ketones, form a central scaffold of various plant flavonoids and isoflavonoids. This family has been documented with diverse biological function, including antibacterial, antifungal, anti-inflammatory, anticancer, antiproliferative and antidiabetic activities and some of them have received approval for clinical application or tested in humans. 3, 4 Notably, synthetic heterocyclic chalcones, whose either ring A or ring B of the original structure is replaced by heteroaryl moieties hold promise as potential agents for cytotoxic activities on various cancer cell lines. 5 Thus, the identification of new heterocyclic chalcones with anticancer activities is of great interest. Towards this objective, we have synthesized 20 heterocyclic chalcone compounds and evaluated for their cytotoxicity on rhabdomyosarcoma (RD-A) cells by MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) cell proliferation assay 7 .
MATERIALS AND METHODS

Chemical synthesis
Chemical reagents were purchased from Acros, Merck and Sigma Aldrich used directly without further purification. Heterocyclic chalcones in this study were developed on the basis of the idea that heteroaryl moieties either on ring A or ring B of chalcones might trigger cytotoxicity on cancer cells. The structures of studied compounds were shown in Table 1 .
Scheme 1. General key step for the synthesis of chalcones
General procedure: to solution of Acetyl heteroaryl ketone (2 mmol) and appropriated aromatic aldehyde (2 mmol) in methanol (15 mL) cooled to 5-10°C in an ice bath added a small portion of pulverized KOH (2.5 mmol). The reaction mixture was magnetically stirred for 60 minutes and then left overnight or longer, monitored by T.L.C. The reaction mixture was diluted with ice water and carefully neutralized using diluted HCl acid. The target chalcone which separated as yellow solid was further purified by crystallization from methanol. All the synthesized chalcones were taken their analytical spectroscopy and elucidated structure (data not showed).
Evaluation of cytotoxic activities
General procedure: RD-A cells suspension was harvested from the EMEM medium containing 10% FCS, 2 mM L-glutamine and 100 IU/ml penicillin. The samples were prepared in DMSO in the 5 concentrations of 100; 50; 25; 12.5 and 6.25 µM. The cells were incubated in 96-well plates and treated with samples at 5 different concentrations in 24 hours. After removal of the incubation medium, 0.05 mg/mL MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) was added and the wells was subjected to continued incubation in 3 hours with 5% CO2 at 37 o C. Absorbance values at the wavelength of 570 nm were recorded using microplate Multiskan TM . The percentage of proliferation inhibition was calcutated as following: % Proliferation inhbition = 100 -(Asample/Acontrol) × 100 Assay was performed in duplicate and IC50 was deduced by linear regression of the inhibitory percentage -log (concentration). 
RESULTS AND DISCUSSION
CONCLUSIONS
Several lines of investigation suggest that heterocyclic chalcone compounds may be effective anticancer agents. The study presented herein demonstrates that some representative heterocyclic chalcones, namely, phenothiazinyl chalcones and pyridinyl chalcones exhibit promising anticancer properties. These structures are simpler than those of anticancer drugs using for chemotherapy recently. As a result, these compounds may be promising leads for the development of effective anticancer agents.
